GlaxoSmithKline To Stop MAGRIT Trial

April 2, 2014 6:48 AM

4
0

GlaxoSmithKline Plc. (GSK: Quote,GSK.L) Wednesday announced its decision to stop the MAGRIT trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer or NSCLC patients, after establishing that it would not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. Data from the trial announced on March 20 showed that it did not meet its first or second co-primary endpoints as it did not significantly extend disease-free survival when compared to placebo in either the overall MAGE-A3 positive population, first co-primary endpoint, or in those MAGE-A3-positive patients who did not receive chemotherapy, which was the second co-primary endpoint.

GSK continued with the MAGRIT trial to investigate the third co-primary endpoint of disease-free survival in a gene signature positive sub-population, which was designed to identify a subset of MAGE-A3 positive patients that may benefit from the treatment.